Bio-Rad Laboratories (NYSE:BIO.B) Releases Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $2.54 earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $585.40 million for the quarter. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO.B remained flat at $234.41 during trading on Monday. The stock had a trading volume of 11 shares, compared to its average volume of 218. The firm's 50-day simple moving average is $251.20 and its two-hundred day simple moving average is $305.84. Bio-Rad Laboratories has a 52-week low of $225.29 and a 52-week high of $359.22. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $6.57 billion, a price-to-earnings ratio of -3.60 and a beta of 0.94.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.